Hagen Cramer, PhDQurAlis における Chief Technology Officerスピーカー
プロフィール
Dr. Hagen Cramer is a renowned expert in all chemistry related aspects of oligonucleotide therapeutic development. He has been working in the biotech industry for over 25 years spanning discovery, development and manufacturing of oligonucleotide-based therapeutics. Early in his career he worked with Gemini Technologies and Ridgway Biosystems on the discovery of 2-5A antisense for the treatment of a variety of cancers and viral diseases. In 2005 he joined Girindus, which was later acquired by Nitto Denko Avecia where he headed the process development department eventually becoming Director of Operations. More recently he joined Wave Life Sciences where he was responsible for securing drug substance and drug product for its clinical pipeline of stereodefined oligonucleotide therapeutics. In 2020 he joined QurAlis as Chief Technology Officer supporting all programs targeting diseases affecting the CNS.